## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 3.36 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($537.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Union Bancaire Privee UBP SA Sells 6,405 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251217T140758 | Somewhat-Bullish | Relevance: 100%
- Union Bancaire Privee UBP SA significantly reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by selling 6,405 shares, now holding 17,630 shares valued at $7.885 million. This divestment comes despite Intuitive Surgical exceeding Q3 earnings expectations, with analysts maintaining a "Moderate Buy" consensus and an average price target of $609.83. Concurrently, there has been notable insider selling, with 114,007 shares sold over the past 90 days, while institutional investors collectively hold 83.64% of the stock.

**2. Assenagon Asset Management S.A. Sells 840,025 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251217T100755 | Neutral | Relevance: 100%
- Assenagon Asset Management S.A. significantly reduced its stake in Intuitive Surgical, Inc. by selling 840,025 shares, representing a 53.1% cut. Despite this institutional selling, Intuitive Surgical exceeded Q3 earnings and revenue estimates, maintaining a "Moderate Buy" consensus among analysts with an average price target of $608.79. Recent insider selling also occurred, while the company's stock shows a fifty-day moving average of $534.09.

**3. Hereâ€™s What Hit Intuitive Surgical (ISRG) in Q3**
- Source: Insider Monkey | 20251217T082700 | Somewhat-Bullish | Relevance: 100%
- Sands Capital Global Growth Fund reported challenges for Intuitive Surgical, Inc. (NASDAQ: ISRG) in Q3 2025, with shares declining due to fears about U.S. hospital budgets and a broader healthcare sector underperformance. Despite this, the company exceeded consensus expectations with strong fundamental results, including a 22% rise in Da Vinci 5 placements and stock repurchases, positioning it well for its next robot upgrade cycle. The stock closed at $554.58 on December 16, 2025, with a market cap of $198.804 billion.

**4. Intuitive Surgical Stock (ISRG) News Today: Price Action, Analyst Forecasts, and What to Watch on December 16, 2025**
- Source: ts2.tech | 20251216T170827 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) saw a 2% intraday dip on December 16, 2025, to $548-$549, following a strong rebound, with its market cap around $194 billion. The stock is drawing attention due to improving "Relative Strength" signals, institutional rebalancing, insider selling, and analyst forecasts for its continued growth into 2026. Key catalysts include the recent FDA clearance expanding da Vinci SP indications, and investors are keenly watching Q4 results in late January 2026 for further signals on procedure growth and system placements.

**5. Stocks showing improving market leadership: Intuitive Surgical earns 81 RS rating**
- Source: MSN | 20251216T160116 | Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) has seen an improvement in its Relative Strength (RS) Rating, which increased from 79 to 81. This upgrade indicates a stronger performance compared to other stocks in the market. The RS Rating is a crucial indicator for investors looking for top-performing stocks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.4x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +4.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.36 signals overvaluation risk, limited margin of safety. Forward P/E 57.6x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $201.4B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.36 |
| Forward P/E | 57.6 |
| Current P/E | 65.0 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -2.3% to 2.0% (+4.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-3.07), momentum weakening. RSI neutral at 54. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.99% (CS: 67) | Neutral |
| RSI_14 | 54.5 | Neutral |
| MACD Histogram | -3.07 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $561.89
- **Stop Loss:** $537.03 (4.4% risk)
- **Target:** $586.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $21,351.82
- **Portfolio %:** 21.35%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*